China NT Pharma Group Co (HKSE:01011) LT-Debt-to-Total-Asset : 0.01 (As of Jun. 2024)

View and export this data going back to 2011. Start your Free Trial

What is China NT Pharma Group Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. China NT Pharma Group Co's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.01.

China NT Pharma Group Co's long-term debt to total assets ratio increased from Jun. 2023 (0.00) to Jun. 2024 (0.01). It may suggest that China NT Pharma Group Co is progressively becoming more dependent on debt to grow their business.

China NT Pharma Group Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for China NT Pharma Group Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China NT Pharma Group Co LT-Debt-to-Total-Asset Chart

China NT Pharma Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

0.22

0.01

China NT Pharma Group Co Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.22	-	-	0.01	0.01

China NT Pharma Group Co LT-Debt-to-Total-Asset Calculation

China NT Pharma Group Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	3.938	/	359.987
	=	0.01

China NT Pharma Group Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	3.837	/	364.694
	=	0.01

China NT Pharma Group Co (HKSE:01011) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

China NT Pharma Group Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of China NT Pharma Group Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

China NT Pharma Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China NT Pharma Group Co Ltd (HKSE:01011) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

198 Wellington Street, 28th Floor, The Wellington, Sheung Wan, Hong Kong, HKG

Website

http://www.ntpharma.com

China NT Pharma Group Co Ltd is a technology-based pharmaceutical company. It is engaged in research and development, production, and sale of private-label drugs, as well as the provision of pharmaceutical marketing and promotion services in China. It focused on the research, development, production, and sales of orthopedic, psychiatric, and oncology drugs. The company operates in a single segment of Proprietary product production and sales. The company earns the majority of its revenue from the domestic market. The Group's revenue from an external customer was derived solely from its operations in the PRC.

Executives

Ieong Chong Mang
Golden Base Investment Limited
Shum Ning
Chin Yu
Ng Tit
Wang Minzhi	2101 Beneficial owner

China NT Pharma Group Co Headlines

No Headlines